Companies Blueprint Medicines Corp
Blueprint Medicines (BPMC): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Blueprint Medicines Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers76th pct.Of 17 peer CEOs
CEO pay, last three years
- $6,217,694FY2022
- $6,432,012FY2023
- $13,477,004FY2024
CEO total pay was $13,477,004 in fiscal 2024, up from $6,432,012 in fiscal 2023.
FY2024: salary $821,363 · bonus $0 · stock awards $7,472,480 · option awards $4,315,144
Executives and directors
Percy Carter · Chief Scientific OfficerFouad Namouni · PresidentChristina Rossi · COOKathryn Haviland · CEOMichael Landsittel · CFOAlexis Borisy · Independent DirectorDaniella Beckman · Independent DirectorHabib Dable · Independent DirectorJeffrey W. Albers · Chair of the BoardJohn Tsai · Independent DirectorLonnel Coats · Independent DirectorLynn Seely · Lead Independent DirectorMark Goldberg · Independent DirectorNicholas Lydon · Independent Director
Frequently asked questions
Who was the highest-paid executive at Blueprint Medicines Corp in fiscal 2024?
As disclosed, Kathryn Haviland (President and Chief Executive Officer) was the highest-paid executive at Blueprint Medicines Corp in fiscal 2024, with total compensation of $13,477,004.
How does Blueprint Medicines Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Kathryn Haviland's total compensation ranked at the 76th percentile of Blueprint Medicines Corp's disclosed peer group.
What is Blueprint Medicines Corp's CEO-to-median employee pay ratio?
As disclosed, Blueprint Medicines Corp's CEO-to-median employee pay ratio was 35:1.
How did shareholders vote on Blueprint Medicines Corp's executive compensation?
As disclosed, 95.93% of shareholders supported Blueprint Medicines Corp's executive compensation in the latest say-on-pay vote.
How much does Blueprint Medicines Corp spend in total on board compensation for fiscal 2024?
As disclosed, Blueprint Medicines Corp reported total board compensation of $2,804,894 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kathryn Haviland | $821,363 | $0 | $7,472,480 | $4,315,144 | $854,217 | $0 | $13,800 | $13,477,004 |
| President and Chief Executive Officer | ||||||||
| Christina Rossi | 668,410 | 0 | 3,700,218 | 1,618,179 | 541,412 | 0 | 13,800 | 6,542,019 |
| Chief Operating Officer | ||||||||
| Fouad Namouni | 671,809 | 0 | 2,649,360 | 1,618,179 | 544,165 | 0 | 13,800 | 5,497,313 |
| President, Research and Development | ||||||||
| Percy Carter | 619,233 | 0 | 2,687,050 | 1,348,483 | 417,982 | 0 | 59,715 | 5,132,463 |
| Chief Scientific Officer | ||||||||
| Michael Landsittel | 573,593 | 0 | 1,868,200 | 1,348,483 | 387,175 | 0 | 13,800 | 4,191,251 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Kathryn Haviland | $13,477,004 | $6,432,012 | $6,217,694 | ↑ +7,044,992 |
| Christina Rossi | 6,542,019 | 2,806,209 | 2,769,000 | ↑ +3,735,810 |
| Fouad Namouni | 5,497,313 | 2,801,778 | 2,810,182 | ↑ +2,695,535 |
| Percy Carter | 5,132,463 | 2,299,827 | 1,992,743 | ↑ +2,832,636 |
| Michael Landsittel | 4,191,251 | 2,194,830 | 2,363,511 | ↑ +1,996,421 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation program is designed to promote company performance and reward value creation for stockholders by attracting, engaging, and retaining highly skilled executive talent. It aligns executives' interests with stockholders through long-term incentives linked to stock price performance and provides incentives that motivate the achievement of performance goals directly tied to business objectives and stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Landsittel | RSU | 2024-03-01 | — | — | 12,500 | — | $1,189,000 |
| Kathryn Haviland | PSU | 2024-03-01 | 13,500 | 27,000 | — | 54,000 | 3,667,680 |
| Michael Landsittel | PSU | 2024-03-01 | 2,500 | 5,000 | — | 10,000 | 679,200 |
| Fouad Namouni | PSU | 2024-03-01 | 4,500 | 9,000 | — | 18,000 | 1,222,560 |
| Percy Carter | PSU | 2024-03-01 | 2,500 | 5,000 | — | 10,000 | 679,200 |
| Christina Rossi | RSU | 2024-07-01 | — | — | 9,625 | — | 1,050,858 |
| Christina Rossi | PSU | 2024-03-01 | 4,500 | 9,000 | — | 18,000 | 1,222,560 |
| Fouad Namouni | OPTION | 2024-03-01 | — | — | 30,000 | — | 1,618,179 |
| Percy Carter | OPTION | 2024-03-01 | — | — | 25,000 | — | 1,348,483 |
| Percy Carter | RSU | 2024-07-01 | — | — | 7,500 | — | 818,850 |
| Kathryn Haviland | RSU | 2024-03-01 | — | — | 40,000 | — | 3,804,800 |
| Christina Rossi | RSU | 2024-03-01 | — | — | 15,000 | — | 1,426,800 |
| Kathryn Haviland | OPTION | 2024-03-01 | — | — | 80,000 | — | 4,315,144 |
| Percy Carter | RSU | 2024-03-01 | — | — | 12,500 | — | 1,189,000 |
| Michael Landsittel | OPTION | 2024-03-01 | — | — | 25,000 | — | 1,348,483 |
| Fouad Namouni | RSU | 2024-03-01 | — | — | 15,000 | — | 1,426,800 |
| Christina Rossi | OPTION | 2024-03-01 | — | — | 30,000 | — | 1,618,179 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Landsittel | $1,189,000 | $679,200 | $1,348,483 | 21.1% |
| Kathryn Haviland | 3,804,800 | 3,667,680 | 4,315,144 | 31.1% |
| Fouad Namouni | 1,426,800 | 1,222,560 | 1,618,179 | 28.6% |
| Percy Carter | 2,007,850 | 679,200 | 1,348,483 | 16.8% |
| Christina Rossi | 2,477,658 | 1,222,560 | 1,618,179 | 23.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kathryn Haviland | Option | 1,633 | 100.13 | — |
| Michael Landsittel | Option | 1,633 | 100.13 | — |
| Christina Rossi | Option | 1,633 | 100.13 | — |
| Fouad Namouni | Option | 1,633 | 100.13 | — |
| Michael Landsittel | PSU | 2,700 | — | 418,261 |
| Percy Carter | PSU | 2,700 | — | 418,261 |
| Kathryn Haviland | RSU | 3,265 | — | 284,773 |
| Michael Landsittel | RSU | 3,265 | — | 284,773 |
| Christina Rossi | RSU | 3,265 | — | 284,773 |
| Fouad Namouni | RSU | 3,265 | — | 284,773 |
| Percy Carter | RSU | 4,374 | — | 381,500 |
| Percy Carter | Option | 4,900 | 89.16 | — |
| Michael Landsittel | PSU | 5,000 | — | 495,017 |
| Percy Carter | PSU | 5,000 | — | 495,017 |
| Christina Rossi | PSU | 5,400 | — | 836,522 |
| Fouad Namouni | PSU | 5,400 | — | 836,522 |
| Percy Carter | RSU | 5,460 | — | 476,221 |
| Percy Carter | Option | 5,469 | 61.31 | — |
| Michael Landsittel | RSU | 6,250 | — | 545,125 |
| Percy Carter | RSU | 7,500 | — | 645,150 |
| Christina Rossi | RSU | 7,500 | — | 654,150 |
| Fouad Namouni | RSU | 7,500 | — | 654,150 |
| Michael Landsittel | Option | 7,813 | 61.31 | — |
| Christina Rossi | PSU | 9,000 | — | 891,031 |
| Fouad Namouni | PSU | 9,000 | — | 891,031 |
| Michael Landsittel | RSU | 9,375 | — | 817,688 |
| Percy Carter | RSU | 9,375 | — | 817,688 |
| Christina Rossi | Option | 9,375 | 61.31 | — |
| Fouad Namouni | Option | 9,375 | 61.31 | — |
| Christina Rossi | RSU | 9,625 | — | 839,493 |
| Christina Rossi | RSU | 11,250 | — | 981,225 |
| Fouad Namouni | RSU | 11,250 | — | 981,225 |
| Michael Landsittel | RSU | 12,500 | — | 1,090,250 |
| Percy Carter | RSU | 12,500 | — | 1,090,250 |
| Michael Landsittel | Option | 14,063 | 43.15 | — |
| Percy Carter | Option | 14,063 | 43.15 | — |
| Christina Rossi | RSU | 15,000 | — | 1,308,300 |
| Fouad Namouni | RSU | 15,000 | — | 1,308,300 |
| Christina Rossi | Option | 16,875 | 43.15 | — |
| Fouad Namouni | Option | 16,875 | 43.15 | — |
| Kathryn Haviland | RSU | 20,000 | — | 1,744,400 |
| Michael Landsittel | Option | 20,313 | 95.12 | — |
| Percy Carter | Option | 20,313 | 95.12 | — |
| Kathryn Haviland | PSU | 20,700 | — | 3,206,667 |
| Christina Rossi | Option | 24,375 | 95.12 | — |
| Fouad Namouni | Option | 24,375 | 95.12 | — |
| Kathryn Haviland | Option | 25,000 | 61.31 | — |
| Kathryn Haviland | PSU | 27,000 | — | 2,673,092 |
| Kathryn Haviland | RSU | 30,000 | — | 2,616,600 |
| Kathryn Haviland | RSU | 40,000 | — | 3,488,800 |
| Kathryn Haviland | Option | 45,000 | 43.15 | — |
| Kathryn Haviland | Option | 65,000 | 95.12 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Lynn SeelyIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance | $106,500 | $237,966 | $261,724 | — | — | $606,190 |
| Mark GoldbergIndependent · Audit · Compensation | 72,000 | 237,966 | 261,724 | — | 15,000 | 586,690 |
| Jeffrey W. AlbersNot independent · Board Chair | 86,500 | 237,966 | 261,724 | — | — | 586,190 |
| Daniella BeckmanIndependent · Audit (Chair) | 75,000 | 237,966 | 261,724 | — | — | 574,690 |
| Lonnel CoatsIndependent · Audit · Nominating/Governance (Chair) | 72,900 | 237,966 | 261,724 | — | — | 572,590 |
| Nicholas LydonIndependent · Not standing for re-election | 50,000 | 237,966 | 261,724 | — | 20,000 | 569,690 |
| Habib DableIndependent · Compensation · Nominating/Governance | 65,300 | 237,966 | 261,724 | — | — | 564,990 |
| John TsaiIndependent | 50,000 | 237,966 | 261,724 | — | — | 549,690 |
| Alexis BorisyIndependent | 50,000 | 237,966 | 261,724 | — | — | 549,690 |
| Kathryn HavilandEmployee director · Partial-year service | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 10,000 |
| Stock ownership guideline | All of our directors are in compliance with our current stock ownership guidelines. See “Other Compensation Policies and Practices – Stock Ownership Guidelines” for more information. |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $628,200 |
| Equity awards (grant-date value) | $2,141,694 |
| All other compensation | $35,000 |
| Total cost of the board | $2,804,894 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Blueprint Medicines as a peer
Companies that benchmark against BPMC
32 companies name BPMC as a compensation peer
The list of companies that name BPMC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
APLS Apellis Pharmaceuticals, Inc.DCPH Deciphera Pharmaceuticals, Inc.MRTX Mirati Therapeutics, Inc.UTHR United Therapeutics, Inc.PTCT PTC TherapeuticSRPT Sarepta Therapeutics, Inc.RARE Ultragenyx Pharmaceutical Inc.HALO Halozyme Therapeutics, Inc.ALKS Alkermes, Inc.ACAD ACADIA Pharmaceuticals Inc.BCRX BioCryst Pharmaceuticals, Inc.NBIX Neurocrine Biosciences, Inc.FOLD Amicus Therapeutics, Inc.AGIO Agios Pharmaceuticals, Inc.IONS Ionis Pharmaceuticals, Inc.CRSP CRISPR Therapeutics AGEXEL Exelixis, Inc.
Peer reciprocity
The companies Blueprint Medicines Corp names as compensation peers that name it back in their own disclosed peer groups.
Apellis Pharmaceuticals, Inc. (APLS)258PTC Therapeutic (PTCT)259Sarepta Therapeutics, Inc. (SRPT)260Ultragenyx Pharmaceutical Inc. (RARE)261Halozyme Therapeutics, Inc. (HALO)262Amicus Therapeutics, Inc. (FOLD)263Agios Pharmaceuticals, Inc. (AGIO)264Ionis Pharmaceuticals, Inc. (IONS)265CRISPR Therapeutics AG (CRSP)266
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutic | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 4 | United Therapeutics, Inc. | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 5 | Blueprint Medicines Corp | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 6 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 7 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 8 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 9 | Mirati Therapeutics, Inc. | 2022 | David Meek | 749,423 | 6,043,885 | 4,233,427 | 438,985 | 11,937,371 |
| 10 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 11 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 12 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 13 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Alkermes, Inc. | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 15 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 16 | Crispr Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 17 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 18 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Blueprint Medicines Corp | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Alkermes, Inc. | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Crispr Therapeutics AG | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Deciphera Pharmaceuticals, Inc. | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Mirati Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon Human Capital Solutions and Alpine Rewards |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutic | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics, Inc. | 221% | PSO 50 · PSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-18 | 57,714,069 | 2,450,825 | 25,744 | 95.93% | Passed |
| 2024 | 2024-04-25 | 56,844,879 | 1,345,313 | 84,037 | 97.69% | Passed |
| 2023 | 2023-06-21 | 54,299,704 | 1,010,255 | 43,914 | 98.17% | Passed |
| 2022 | 2022-06-21 | 53,277,135 | 916,091 | 26,152 | 98.31% | Passed |
| 2021 | 2021-06-02 | 51,256,830 | 1,208,065 | 10,839 | 97.7% | Passed |
| 2020 | 2020-06-23 | 46,685,705 | 963,650 | 16,055 | 97.98% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-18 | 95.93%a |
| 2024 | 2024-04-25 | 97.69%b |
| 2023 | 2023-06-21 | 98.17%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 35 : 1 |
|---|---|
| CEO total compensation | $13,477,004 |
| Median employee compensation | $389,871 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christina Rossi | Chief Operating Officer | 2025-05-05 | D | 607 | $101 | $61,289 | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-05-05 | A | 2,752 | 54 | 148,966 | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-05-05 | D | 1,252 | 103 | 128,343 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-05-05 | D | 180 | 103 | 18,508 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-05-05 | D | 144 | 104 | 14,913 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-05-05 | D | 1,343 | 102 | 136,677 | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-05-05 | D | 2,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-05-05 | D | 100 | 105 | 10,478 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-05-19 | D | 804 | 100 | 80,513 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-05-19 | D | 57 | 102 | 5,798 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-05-19 | D | 1,413 | 101 | 142,247 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | D | 4,350 | 101 | 439,437 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | D | 650 | 102 | 66,255 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | A | 5,000 | 36 | 180,250 | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-06-03 | D | 2,418 | 128 | 309,214 | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-06-03 | D | 241 | 128 | 30,819 | Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-06-18 | A | 3,902 | 12,812 | 49,992,424 | Common | Form 4 ↗ |
| John Tsai | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-03 | D | 1,172 | 128 | 150,309 | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-03 | D | 1,051 | 128 | 134,791 | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 43,175 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 18,254 | — | — | Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 26,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 21,818 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 5,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 144,755 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 7,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 10,842 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 39,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 591 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 20,628 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 13,490 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 9,494 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 8,742 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 2 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 70,729 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 224,410 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 39,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 17,894 | — | — | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 19,271 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 1,607 | — | — | Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 3,188 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 11,818 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 7,007 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 6,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 2,751 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 2,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 3,378 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 51,102 | — | — | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 20,669 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 21,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 15,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 51,103 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 39,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 51,103 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 9,115 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 50,165 | — | — | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 5,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 11,399 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 16,146 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 26,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 83,281 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | A | 39,456 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 31,956 | — | — | Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 74,160 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 70,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 32,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 82,374 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 56,614 | — | — | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 13,254 | — | — | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 110,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 170,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 92,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 6,928 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 13,184 | — | — | Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 50,165 | — | — | Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 30,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 19,856 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 29,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 37,092 | — | — | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 6,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 6,144 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 7,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 8,742 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 7,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | President, R & D | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 5,777 | — | — | Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 19,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 8,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | A | 2,460 | — | — | Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | A | 129,210 | — | — | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | A | 39,456 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (266 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kathryn Haviland. DEF 14A, filed 2025-04-24. Section “2024 Summary Compensation Table” · page 52. As printed: 13,477,004. View filing ↗
- Section 01, Christina Rossi. DEF 14A, filed 2025-04-24. Section “2024 Summary Compensation Table” · page 52. As printed: 6,542,019. View filing ↗
- Section 01, Fouad Namouni. DEF 14A, filed 2025-04-24. Section “2024 Summary Compensation Table” · page 52. As printed: 5,497,313. View filing ↗
- Section 01, Percy Carter. DEF 14A, filed 2025-04-24. Section “2024 Summary Compensation Table” · page 52. As printed: 5,132,463. View filing ↗
- Section 01, Michael Landsittel. DEF 14A, filed 2025-04-24. Section “2024 Summary Compensation Table” · page 52. As printed: 4,191,251. View filing ↗
- Section 03, Michael Landsittel RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Kathryn Haviland PSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Landsittel PSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Fouad Namouni PSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Percy Carter PSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Christina Rossi RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Christina Rossi PSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Fouad Namouni OPTION. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Percy Carter OPTION. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Percy Carter RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Kathryn Haviland RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Christina Rossi RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Kathryn Haviland OPTION. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Percy Carter RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Landsittel OPTION. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Fouad Namouni RSU. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Christina Rossi OPTION. DEF 14A, filed 2025-04-24. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-24. Section “CEO Pay Ratio”. As printed: 35 : 1. View filing ↗
- Section 08, Lynn Seely. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 606,190. View filing ↗
- Section 08, Mark Goldberg. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 586,690. View filing ↗
- Section 08, Jeffrey W. Albers. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 586,190. View filing ↗
- Section 08, Daniella Beckman. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 574,690. View filing ↗
- Section 08, Lonnel Coats. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 572,590. View filing ↗
- Section 08, Nicholas Lydon. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 569,690. View filing ↗
- Section 08, Habib Dable. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 564,990. View filing ↗
- Section 08, John Tsai. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 549,690. View filing ↗
- Section 08, Alexis Borisy. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 549,690. View filing ↗
- Section 08, Kathryn Haviland. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Christina Rossi 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-05-05. Form 4, filed 2025-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-05-19. Form 4, filed 2025-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-05-19. Form 4, filed 2025-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-05-19. Form 4, filed 2025-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-05-27. Form 4, filed 2025-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-05-27. Form 4, filed 2025-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-05-27. Form 4, filed 2025-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-05-27. Form 4, filed 2025-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-06-03. Form 4, filed 2025-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-06-03. Form 4, filed 2025-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tsai 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-06-18. Form 4, filed 2025-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-03. Form 4, filed 2025-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-03. Form 4, filed 2025-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Goldberg 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, L. Becker Hewes 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Durso-Bumpus 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Percy Carter 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tsai 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tsai 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tsai 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tsai 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniella Beckman 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fouad Namouni 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexis Borisy 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Albers 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tsai 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Landsittel 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynn Seely 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ariel Hurley 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philina Lee 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Haviland 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2025-07-17. Form 4, filed 2025-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 95.93% (votes for as printed: 57,714,069). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 97.69% (votes for as printed: 56,844,879). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-27. Item 5.07 · say-on-pay result. As reported: 98.17% (votes for as printed: 54,299,704). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 628,200 + equity 2,141,694 + all other 35,000 = 2,804,894, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- PTC Therapeutic, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutic's own proxy. As printed: 23,266,326. View filing ↗
- Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
- United Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics, Inc.'s own proxy. As printed: 18,038,972. View filing ↗
- Blueprint Medicines Corp (subject), Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corp's own proxy. As printed: 13,477,004. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- BioCryst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. View filing ↗
- Mirati Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-06. CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Alkermes, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes, Inc.'s own proxy. As printed: 7,915,081. View filing ↗
- Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
- Crispr Therapeutics AG, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics AG's own proxy. As printed: 7,678,477. View filing ↗
- Deciphera Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Section 10a, Apellis Pharmaceuticals, Inc. reciprocity. DEF 14A. Apellis Pharmaceuticals, Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, PTC Therapeutic reciprocity. DEF 14A. PTC Therapeutic names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Sarepta Therapeutics, Inc. reciprocity. DEF 14A. Sarepta Therapeutics, Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity. DEF 14A. Ultragenyx Pharmaceutical Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Halozyme Therapeutics, Inc. reciprocity. DEF 14A. Halozyme Therapeutics, Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Amicus Therapeutics, Inc. reciprocity. DEF 14A. Amicus Therapeutics, Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Agios Pharmaceuticals, Inc. reciprocity. DEF 14A. Agios Pharmaceuticals, Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ionis Pharmaceuticals, Inc. reciprocity. DEF 14A. Ionis Pharmaceuticals, Inc. names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, CRISPR Therapeutics AG reciprocity. DEF 14A. CRISPR Therapeutics AG names Blueprint Medicines Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗